Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Pseudomyxoma Peritonei × 1 year × Clear all

Phase

Phase 2 3 Phase NA 2 Phase 3 2 Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 37 Prostatic Neoplasms 30 Glioblastoma 30 Glioma 29 Pancreatic Neoplasms 24 Multiple Myeloma 22 Neoplasms 19 Brain Neoplasms 19 Recurrence 18 Squamous Cell Carcinoma of Head and Neck 15 Leukemia, Myeloid, Acute 15 Lung Neoplasms 14 Head and Neck Neoplasms 13 Colorectal Neoplasms 13 Triple Negative Breast Neoplasms 12 Sarcoma 11 Neoplasm Metastasis 11 Melanoma 11 Hematologic Neoplasms 11 Lymphoma 10 Ovarian Neoplasms 9 Colonic Neoplasms 9 Burkitt Lymphoma 9 Stomach Neoplasms 8 Polycystic Ovary Syndrome 8 Lymphoma, B-Cell 8 Carcinoma, Non-Small-Cell Lung 8 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Myasthenia Gravis 7 Endometrial Neoplasms 7

Interventions

tislelizumab 1 molgramostim 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07341360 2026-01-14

Pseudovax

Oslo University Hospital

Phase EARLY_PHASE1 Recruiting

Pseudomyxoma Peritonei

Data powered by HemOnc (CC BY 4.0) Colophon ⚡